{"groups":[{"description":"Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day\n\ndonepezil hydrochloride: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily","id":"FG000","title":"Arm I - Donepezil"},{"description":"Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day\n\nPlacebo: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day","id":"FG001","title":"Arm II - Control"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"}],"type":"Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Never started"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}],"type":"Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"5"}],"type":"Multiple reasons"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"99"},{"groupId":"FG001","numSubjects":"99"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"74"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"25"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Patients were accrued between 2/2008 and 12/2011 at NCI CCOP sites across the nation."}